Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: Present and future
Ueckert, Stefan ; Hedlund, Petter LU ; Andersson, Karl-Erik LU
; Truss, Michael C.
; Jonas, Udo
and Stief, Christian G.
(2006)
In European Urology
50(6).
p.1194-1207
- Abstract
- Objectives & Methods: Diseases of the human urinary tract represent common morbidities characterized by a high prevalence in the population of most westernized countries. The existeince of a significant number of affected patients and the recent increase in scientific attention has resulted in various experimental and clinical efforts in order to evaluate the mechanisms controlling the function of urinary tract organs. This review attempts to describe the physiology and pharmacology of phosphodiesterase (PDE) isoenzymes with special regard to their (potential) use in disorders of the human urogenital tract. Results: The promising clinical data for the orally active phosphodiesterase (PDE) inhibitors sildenafil, vardenafil and... (More)
- Objectives & Methods: Diseases of the human urinary tract represent common morbidities characterized by a high prevalence in the population of most westernized countries. The existeince of a significant number of affected patients and the recent increase in scientific attention has resulted in various experimental and clinical efforts in order to evaluate the mechanisms controlling the function of urinary tract organs. This review attempts to describe the physiology and pharmacology of phosphodiesterase (PDE) isoenzymes with special regard to their (potential) use in disorders of the human urogenital tract. Results: The promising clinical data for the orally active phosphodiesterase (PDE) inhibitors sildenafil, vardenafil and tadalafil, used in the treatment of male erectile dysfunction (MED), has boosted research activities on the significance of the cyclic GMP- and cyclic AMP pathway in other genitourinary tract tissues, such as the bladder, prostate, ureter, urethra, as well as female genital tissues. Based on the more extensive understanding of the pathways controlling the function of the male and female urogenital tract, orally administered phosphodiesterase inhibitors are considered a logical and straightforward approach for treating urological diseases. Due to the unending charge to conceive advanced first-line treatments, new therapeutic options taking into consideration the cyclic nucleotide signaling have been introduced or might be launched in the near future. Upcoming strategies will not only focus on the nitric oxide (No)/cGMP cascade but also on compounds modulating signal transduction mediated by cyclic adenosine monophosphate, as well as combined agents in order to affect multiple peripheral intracellular targets. Conclusions: The article highlights cGMP- and cAMP-pathways, PDE subtypes and their present or putative future clinical significance in urological practice. (c) 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/685212
- author
- Ueckert, Stefan
; Hedlund, Petter
LU
; Andersson, Karl-Erik
LU
; Truss, Michael C.
; Jonas, Udo
and Stief, Christian G.
- organization
- publishing date
- 2006
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- human urogenital tract, phosphodiesterase (PIDE) enzymes, phosphodiesterase inhibitors
- in
- European Urology
- volume
- 50
- issue
- 6
- pages
- 1194 - 1207
- publisher
- Elsevier
- external identifiers
-
- wos:000242412200013
- scopus:33750633515
- pmid:16815627
- ISSN
- 1873-7560
- DOI
- 10.1016/j.eururo.2006.05.025
- language
- English
- LU publication?
- yes
- id
- e45b9f09-2d33-4876-aed6-406a3a82a5e7 (old id 685212)
- date added to LUP
- 2016-04-01 16:06:53
- date last changed
- 2022-04-07 03:05:41
@article{e45b9f09-2d33-4876-aed6-406a3a82a5e7,
abstract = {{Objectives & Methods: Diseases of the human urinary tract represent common morbidities characterized by a high prevalence in the population of most westernized countries. The existeince of a significant number of affected patients and the recent increase in scientific attention has resulted in various experimental and clinical efforts in order to evaluate the mechanisms controlling the function of urinary tract organs. This review attempts to describe the physiology and pharmacology of phosphodiesterase (PDE) isoenzymes with special regard to their (potential) use in disorders of the human urogenital tract. Results: The promising clinical data for the orally active phosphodiesterase (PDE) inhibitors sildenafil, vardenafil and tadalafil, used in the treatment of male erectile dysfunction (MED), has boosted research activities on the significance of the cyclic GMP- and cyclic AMP pathway in other genitourinary tract tissues, such as the bladder, prostate, ureter, urethra, as well as female genital tissues. Based on the more extensive understanding of the pathways controlling the function of the male and female urogenital tract, orally administered phosphodiesterase inhibitors are considered a logical and straightforward approach for treating urological diseases. Due to the unending charge to conceive advanced first-line treatments, new therapeutic options taking into consideration the cyclic nucleotide signaling have been introduced or might be launched in the near future. Upcoming strategies will not only focus on the nitric oxide (No)/cGMP cascade but also on compounds modulating signal transduction mediated by cyclic adenosine monophosphate, as well as combined agents in order to affect multiple peripheral intracellular targets. Conclusions: The article highlights cGMP- and cAMP-pathways, PDE subtypes and their present or putative future clinical significance in urological practice. (c) 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved.}},
author = {{Ueckert, Stefan and Hedlund, Petter and Andersson, Karl-Erik and Truss, Michael C. and Jonas, Udo and Stief, Christian G.}},
issn = {{1873-7560}},
keywords = {{human urogenital tract; phosphodiesterase (PIDE) enzymes; phosphodiesterase inhibitors}},
language = {{eng}},
number = {{6}},
pages = {{1194--1207}},
publisher = {{Elsevier}},
series = {{European Urology}},
title = {{Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: Present and future}},
url = {{http://dx.doi.org/10.1016/j.eururo.2006.05.025}},
doi = {{10.1016/j.eururo.2006.05.025}},
volume = {{50}},
year = {{2006}},
}